Skip to content
OpenCapital
Get started

Opus Genetics IRD Cash Provided by (Used in) Operating Activity, Including Discontinued Operation

Cash Provided by (Used in) Operating Activity, Including Discontinued Operation at other companies

Sarepta Therapeutics, Inc. logo
Sarepta Therapeutics, Inc.SRPT
-$202.68M+65.3%

Other financials

Income statement

See full
Revenue$2.2M-50.6%
Operating income-$14.4M-44.7%
Net income-$65.5M-700%
EPS (diluted)-$0.75-213%

Balance sheet

See full
Cash & equivalents$60.0M+43.5%
Total debt$1.2M—
Total equity-$45.8M-1,004%
Total assets$66.8M+38.7%

Cash flow

See full
Operating cash flow-$12.7M-41.5%

Valuation

See full
Market cap$307.14M+442%
Enterprise value$248.38M—
P/S25.6×+21.5×

Profitability

See full
Operating margin-359.1%-68.9pp
Net margin-892.4%-12,322pp

Returns & leverage

See full
Return on equity-449.4%-2,573pp
Debt / equity0.1×—
Current ratio7.1×+5.2×

Where this comes from

Reported directly by Opus Genetics in its filing.

Tagged under the XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities.

The official record: Opus Genetics’s 10-Q, filed May 12, 2026, on SEC EDGAR. View the filing →

Ask your AI about Opus Genetics's cash provided by (used in) operating activity, including discontinued operation.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Opus Genetics's cash provided by (used in) operating activity, including discontinued operation?
Opus Genetics (IRD) reported cash provided by (used in) operating activity, including discontinued operation of -$12.73M in Q1 2026.
How has Opus Genetics's cash provided by (used in) operating activity, including discontinued operation changed year-over-year?
Opus Genetics's cash provided by (used in) operating activity, including discontinued operation decreased by 41.5% year-over-year, from -$8.99M to -$12.73M.
What is the long-term trend for Opus Genetics's cash provided by (used in) operating activity, including discontinued operation?
Over 3 years (2021 to 2025), Opus Genetics's cash provided by (used in) operating activity, including discontinued operation has grown at a 22.1% compound annual growth rate (CAGR), from -$19.37M to -$35.25M.
What does cash provided by (used in) operating activity, including discontinued operation mean?
Measures the cash generated from the company's core business operations, excluding financing and investing activities. It reflects the ability of the company to convert revenue into actual cash flow after accounting for changes in working capital.